Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
CC transcript
|
|
Revance Therapeutics, Inc. (RVNC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/15/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 22,620 shares
@ $0
Paid exercise price by delivering 11,215 shares
@ $18.91, valued at
$212.1k
|
|
| 08/15/2023 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 19,346 shares
@ $0
Paid exercise price by delivering 9,592 shares
@ $18.91, valued at
$181.4k
|
|
| 08/15/2023 |
4
| Sjuts Dustin S (President) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 22,620 shares
@ $0
Paid exercise price by delivering 8,901 shares
@ $18.91, valued at
$168.3k
|
|
| 08/15/2023 |
4
| Foley Mark J (CEO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 122,143 shares
@ $0
Paid exercise price by delivering 48,064 shares
@ $18.91, valued at
$908.9k
|
|
| 08/14/2023 |
8-K
| Other Events Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
4
| Foley Mark J (CEO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Sold 26,279 shares
@ $22.5713, valued at
$593.2k
|
|
| 08/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/05/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 769 shares
@ $15.606, valued at
$12k
Sold 1,701 shares
@ $25.04, valued at
$42.6k
|
|
| 07/05/2023 |
4
| Sjuts Dustin S (President) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 1,000 shares
@ $15.606, valued at
$15.6k
|
|
| 07/05/2023 |
4
| Foley Mark J (CEO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 1,000 shares
@ $15.606, valued at
$15.6k
Sold 26,279 shares
@ $24.9375, valued at
$655.3k
|
|
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 07/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/09/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/05/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Sold 2,701 shares
@ $30.57, valued at
$82.6k
Sold 500 shares
@ $31, valued at
$15.5k
|
|
| 06/02/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/01/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/16/2023 |
4
| Moxie Dwight (SVP, GC & Secretary) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 42,349 shares
@ $0
Sold 21,401 shares
@ $34.5469, valued at
$739.3k
|
|
| 05/16/2023 |
4
| Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 42,349 shares
@ $0
Sold 21,401 shares
@ $34.5469, valued at
$739.3k
|
|
| 05/16/2023 |
4
| Foley Mark J (CEO) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 175,649 shares
@ $0
Sold 70,447 shares
@ $34.5469, valued at
$2.4M
|
|
| 05/16/2023 |
4
| Sjuts Dustin S (President) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 52,395 shares
@ $0
Sold 21,015 shares
@ $34.5469, valued at
$726k
|
|
| 05/15/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/08/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/05/2023 |
4
| Gangolli Julian S (Director) has filed a Form 4 on Revance Therapeutics, Inc.|
Txns:
| Granted 3,534 shares
@ $0
Granted 5,915 options to buy
@ $33.61, valued at
$198.8k
|
|
| 05/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|
|
|